Anti-PD-1 antibodies release T cells by inhibiting immune checkpoints, which can then bind to MHC I with increased expression levels on tumor cells via T cell receptors, leading to increased cytotoxicity and tumor cell killing levels (140). This evidence concerns the gene PDCD1 and neoplasm.